Xencor | XNCR - Cash And Equivalent


Xencor reported $28.29M in Cash and Equivalent for its fiscal quarter ending in September of 2025.





Cash And Equivalent Change Date
AbbVie USD 5.63B 838M Sep/2025
Alnylam Pharmaceuticals USD 1.49B 376.56M Sep/2025
Amgen USD 9.13B 316M Dec/2025
Arrowhead Research USD 201.64M 112.94M Dec/2025
AstraZeneca USD 8.14B 1.08B Sep/2025
Biogen USD 3.86B 1.1B Sep/2025
Bristol-Myers Squibb USD 10.21B 5.52B Dec/2025
Cytokinetics USD 225.47M 150.53M Sep/2025
GlaxoSmithKline GBP 3.3B 303M Sep/2025
J&J USD 18.23B 10.35B Sep/2025
MacroGenics USD 80.13M 50.56M Sep/2025
Merck USD 18.17B 10.16B Sep/2025
Novartis USD 9.56B 2.9B Sep/2025
Pfizer USD 1.34B 295M Sep/2025
Regeneron Pharmaceuticals USD 18.87B 16.36B Dec/2025
Roche Holding CHF 7.55B 579M Jun/2025
Xencor USD 28.29M 16.15M Sep/2025